# MOMA-341

Source: https://onco.cc/drugs/moma-341/  
OnCo record `moma-341` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MOMA-341 is an experimental small molecule from MOMA Therapeutics, in phase 1 trials for MSI-high / dMMR solid tumours, colorectal cancer and gastric cancer and other cancers.

## Summary

MOMA-341 is a small molecule (oral, covalent) from MOMA Therapeutics. An oral, potent and selective covalent inhibitor of Werner (WRN) helicase, which MSI-high and mismatch repair deficient tumour cells need to survive; tested alone and with irinotecan or immunotherapy. Its furthest stage is phase 1, for MSI-high / dMMR solid tumours, colorectal cancer, gastric cancer and endometrial cancer. ClinicalTrials.gov registers it in one study linked below. NCT06974110 recruiting (registry, checked 3 Nov 2026); first patient dosed July 2025. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: MOMA-341
- Modality: Small molecule (oral, covalent)
- Mechanism: An oral, potent and selective covalent inhibitor of Werner (WRN) helicase, which MSI-high and mismatch repair deficient tumour cells need to survive; tested alone and with irinotecan or immunotherapy.

## Sources

- MOMA Therapeutics: momatx.com: https://momatx.com/posts/moma-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-for-moma-341/
- MOMA Therapeutics: momatx.com: https://momatx.com/posts/moma-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-moma-313/
- ClinicalTrials.gov: trials of MOMA-341: https://clinicaltrials.gov/search?intr=MOMA-341

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [WRN helicase (MSI-high cancers)](https://onco.cc/targets/wrn/)
- companies: [MOMA Therapeutics](https://onco.cc/companies/moma-therapeutics/)
- trials: [Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06974110/)

---
JSON: https://onco.cc/api/v1/entities/moma-341.json